BUHLMANN News

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis

BÜHLMANN MRP8/14 ELISA: Anink J et al.: MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Research and Therapy. 2015: 17:200 PMID: 26249667  doi:  10.1186/s13075-015-0723-1 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Review of biomarkers in systemic juvenile idiopathic arthritis

BÜHLMANN MRP8/14 ELISA: Rothmund F et al.: Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Research (Hoboken). 2014: 66(6):949-55. PMID: 27411444   DOI: 10.1186/s13075-016-1069-z Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort

BÜHLMANN MRP8/14 ELISA: García-Arias M et al.: Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Molecular Diagnosis and Therapy. 2013: 17(1):49-56.  PMID: 23329363 DOI: 10.1007/s40291-013-0016-9 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Can mHealth Apps replace clinic visits?

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. Highlight from this Article In this study, 233 separate apps were found on
Continue Reading

Introducing Patient Home Tests for Calprotectin in a Routine District General Hospital

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article “In the six months that we have been working with the IBDoc, one patient was
Continue Reading

Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis

BÜHLMANN sCAL ELISA: Andrés Cerezo et al.: Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Research and Therapy. 2011; 13(4).  PMID: 21791097  DOI: 10.1186/ar3426 . Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in
Continue Reading

BUHLMANN LabSense News Summer 2018 Edition

In this "Summer Edition" we are pleased to announce the FDA 510 (k) clearance of the BÜHLMANN fCAL® ELISA. We make mention of upcoming meetings where you can find us such as American Association of Clinical Chemistry (AACC) and the Association of Medical Laboratory Immunologists (AMLI) annual meetings. Additionally, we share the exciting happenings pertaining to
Continue Reading

IBDoc – SwissMedtech Award Nominee

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 BÜHLMANN was nominated to receive the Swiss Medtech Award for 2018 for the IBDoc® calprotectin smartphone-based rapid test    About Swiss MEDTECH Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster.
Continue Reading

First IBD Nurse Led IBDoc Study

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster   "The BÜHLMANN IBDoc® adds
Continue Reading

Calprotectin Testing Goes Mobile

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article from Amanda Appleton, the Product Manager for Calprotectin at BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article     “App technology has the ability not only to improve the health of patients but
Continue Reading